A phase Ib trial of fulvestrant+CDK4/6 inhibitor (CDK4/6i) palbociclib plus pan-FGFR tyrosine kinase inhibitor (TKI) erdafitinib in FGFR-amplified/ER+/HER2-negative metastatic breast cancer (MBC)

被引：0
|
作者：
Mayer, Ingrid A. [1 ]
Haley, Barbara B. [2 ]
Abramson, Vandana G. [1 ]
Brufsky, Adam [3 ]
Rexer, Brent [1 ]
Stringer-Reasor, Erica [4 ]
Jhaveri, Komal L. [5 ]
Sanders, Melinda [1 ]
Ericsson-Gonzalez, Paula I. [1 ]
Ye, Fei [1 ]
Arteaga, Carlos L. [2 ]
机构：
[1] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[2] UTSW Simmons Canc Ctr, Dallas, TX USA
[3] UPMC, Magee Womens Hosp, Pittsburgh, PA USA
[4] Univ Alabama Birmingham, Birmingham, AL USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD1-03
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i)
    Mainor, Candace Bavette
    Barrows, Elizabeth Dominic
    Wang, Hongkun
    Lynce, Filipa
    Ashai, Nadia
    Collins, Julie Marie
    Swanson, Nicole
    Castle, Julie
    Novielli, Antonella
    Slingerland, Joyce
    Isaacs, Claudine
    Pohlmann, Paula R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER+/HER2-negative advanced breast cancer (ABC)
    Galardi, F.
    Biagioni, C.
    De Luca, F.
    Curigliano, G.
    Minisini, A. M.
    Bonechi, M.
    Moretti, E.
    Risi, E.
    Migliaccio, I.
    McCartney, A.
    Benelli, M.
    Romagnoli, D.
    Conti, V.
    Biganzoli, L.
    Di Leo, A.
    Malorni, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S18 - S18
  • [3] Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pretreated ER+/HER2- Metastatic Breast Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 9 - 10
  • [4] AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation
    Wander, Seth A.
    Micalizzi, Douglas S.
    Dubash, Taronish
    Juric, Dejan
    Spring, Laura M.
    Vidula, Neelima
    Keenan, Jennifer
    Beeler, Maureen
    Viscosi, Elene
    Che, Dante
    Fisher, Elizabeth L.
    Hepp, Rachel A.
    Moy, Beverly
    Isakoff, Steven J.
    Ellisen, Leif W.
    Supko, Jeffrey G.
    Maheswaran, Shyamala
    Haber, Daniel A.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [5] First-line CDK4/6 inhibitor treatment for HR+, HER2-negative metastatic breast cancer (MBC)
    Hoskins, Kent F.
    Richards, Paul
    Wisinski, Kari
    CANCER RESEARCH, 2018, 78 (13)
  • [6] Prescribing preferences for hormone sensitive (HR plus ) metastatic breast cancer (mBC) in the CDK 4/6 inhibitor (CDK 4/6i) era.
    Feinberg, Bruce A.
    Wojtynek, Jeffrey
    Dokubo, Igoni
    Jeune-Smith, Yolaine
    Kish, Jonathan
    Gajra, Ajeet
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2-Metastatic Breast Cancer
    Mayer, Erica L.
    Ren, Yue
    Wagle, Nikhil
    Mahtani, Reshma
    Ma, Cynthia
    DeMichele, Angela
    Cristofanilli, Massimo
    Meisel, Jane
    Miller, Kathy D.
    Jolly, Trevor
    Riley, Elizabeth
    Qamar, Rubina
    Sharma, Priyanka
    Reid, Sonya
    Sinclair, Natalie
    Faggen, Meredith
    Block, Caroline
    Ko, Naomi
    Partridge, Ann
    Chen, Wendy Y.
    Demeo, Michelle K.
    Attaya, Victoria
    Okpoebo, Amanda
    Liu, Yuan
    Gauthier, Eric
    Burstein, Harold
    Regan, Meredith
    Tolaney, Sara
    CANCER RESEARCH, 2023, 83 (05)
  • [8] A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor
    Roy, Tina
    Barrows, Elizabeth
    Mainor, Candace
    Collins, Julie
    Lynce, Filipa
    Isaacs, Claudine
    Pohlmann, Paula R.
    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2023, 33
  • [9] Genomic Landscape of ER+/HER2-metastatic breast cancer as a function of prior treatment with a CDK4/6 inhibitor
    Chica-Parrado, M. Rosario
    Chica-Parrado, M. Rosario
    Lin, Chang-Ching
    Mahoney, Timothy
    Mauer, Elizabeth
    Hanker, Ariella
    Arteaga, Carlos
    CANCER RESEARCH, 2023, 83 (05)
  • [10] A phase I/IIb study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2-metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II study
    Barroso-Sousa, Romualdo
    Li, Tianyu
    Trippa, Lorenzo
    Rees, Rebecca
    Andrews, Chelsea
    Ferreira, Arlindo R.
    Helvie, Karla
    Partridge, Ann H.
    Overmoyer, Beth
    Winer, Eric P.
    Wagle, Nikhil
    Tolaney, Sara M.
    CANCER RESEARCH, 2020, 80 (04)
12345